



*JPW*

PATENT  
ATTORNEY DOCKET NO. 50291/004002

Certificate of Mailing: Date of Deposit: April 24, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Jeremy Waterman

Printed name of person mailing correspondence

*Jeremy Waterman*

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Robert Chalifour et al.	Art Unit:	1649
Serial No.:	10/825,958	Examiner:	Kimberly A. Ballard
Filed:	April 16, 2004	Customer No.:	21559
Title:	Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: April 24, 2006

Susan M. Michaud  
Susan M. Michaud, Ph.D.  
Reg. No. 42,885

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

Attorney Docket No.	50291/004002
Serial No.	10/825,958
Applicant	Robert Chalifour et al.
Filing Date	April 16, 2004
Group	1649
IDS Filed	April 24, 2006

## U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	6,022,859	02/08/00	Kiessling et al.			
	6,331,440	12/18/01	Nordstedt et al.			

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	00/72880	12/07/00	WIPO			
	01/39796	06/07/01	WIPO			

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Chen et al., "Neurodegenerative Alzheimer-Like Pathology in PDAPP 717V→F Transgenic Mice," Prog. in Brain Res. 117:327-334, 1998.
	Cribbs et al., "All-D-Enantiomers of Beta-Amyloid Exhibit Similar Biological Properties to All-L-Beta-Amyloids," J. Biol. Chem. 272:7431-7436, 1997.
	Games et al., "Alzheimer-Type Neuropathology in Transgenic Mice Overexpressing V717F Beta-Amyloid Precursor Protein," Nature 373(6514):523-527, 1995.
	Jobling et al., "Analysis of Structure and Function of the B Subunit of Cholera Toxin by the Use of Site-Directed Mutagenesis," Mol. Microbiol. 5(7):1755-1767, 1991.
	Lemere et al., "Mucosal Administration of A $\beta$ Peptide Decreases Cerebral Amyloid Burden in PD-APP Transgenic Mice," Society for Neuroscience Abstracts, vol. 25, part 1, Abstract 519.6, 29 <sup>th</sup> Annual Meeting 10/23-10/28, 1999.
	Münch et al., "Potential Neurotoxic Inflammatory Responses to A $\beta$ Vaccination in Humans," J. Neural Transmission 109(7-8):1081-1087, 2002.
	Skolnick et al., "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era," Trends in Biotech. 18(1):34-39, 2000.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.